Newsroom
Sorted by: Latest
-
KGC Investors Have Opportunity to Join Kinross Gold Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--KGC Investors Have Opportunity to Join Kinross Gold Corporation Fraud Investigation with SBS Law...
-
FLUT Investors Have Opportunity to Join Flutter Entertainment plc Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--FLUT Investors Have Opportunity to Join Flutter Entertainment plc Fraud Investigation with SBS Law...
-
FISN Investors Have Opportunity to Join Deep Fission, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--FISN Investors Have Opportunity to Join Deep Fission, Inc. Fraud Investigation with SBS Law...
-
NCPL Investors Have Opportunity to Join Netcapital Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--NCPL Investors Have Opportunity to Join Netcapital Inc. Fraud Investigation with SBS Law...
-
NEOG Investors Have Opportunity to Join Neogen Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--NEOG Investors Have Opportunity to Join Neogen Corporation Fraud Investigation with SBS Law...
-
DASH Investors Have Opportunity to Join DoorDash, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--DASH Investors Have Opportunity to Join DoorDash, Inc. Fraud Investigation with SBS Law...
-
QBTS Investors Have Opportunity to Join D-Wave Quantum Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--QBTS Investors Have Opportunity to Join D-Wave Quantum Inc. Fraud Investigation with SBS Law...
-
SFIX Investors Have Opportunity to Join Stitch Fix, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)--SFIX Investors Have Opportunity to Join Stitch Fix, Inc. Fraud Investigation with SBS Law...
-
Zach Bryan Sets Record for Most Attended Event in Gillette Stadium History
FOXBOROUGH, Mass.--(BUSINESS WIRE)--Zach Bryan broke the Gillette Stadium attendance record on Saturday night, October 3, performing for 73,538 fans as part of his With Heaven On Tour....
-
Agenus تعلن عن معدل بقاء تقديري لمدة ثلاث سنوات بنسبة 48% عند استخدام العلاج المركب (BOT+BAL) لحالات سرطان المبيض المتكرر، وذلك خلال مؤتمر IGCS 2026
ليكسينغتون، ماساتشوستس--(BUSINESS WIRE)--أعلنت شركة .Agenus Inc (المدرجة في بورصة ناسداك تحت الرمز: AGEN)، وهي الشركة الرائدة في مجال الابتكار في العلاج المناعي للسرطان- عن نتائج المتابعة لمدة ثلاث سنوات الخاصة بمجموعة مريضات سرطان المبيض ضمن تجربتها السريرية (C-800-01) من المرحلة (1b)، والتي شملت أكثر من 400 مريض. وقد قيّمت الدراسة عقار "بوتنسيليماب" (BOT) -وهو جسم مضاد لـ CTLA-4 متعدد الوظائف ومُعزَّز بمنطقة Fc من تطوير شركة Agenus- عند استخدامه بالاشتراك مع عقار "بالستيليماب" (BAL)، وهو الجسم...
